pyrimidin-2-one beta-ribofuranoside has been researched along with Acute Promyelocytic Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borutinskaite, VV; Bruzaite, R; Jonusiene, V; Navakauskiene, R; Savickiene, J; Treigyte, G | 1 |
| Borutinskaite, VV; Navakauskiene, R; Savickiene, J; Treigyte, G | 1 |
2 other study(ies) available for pyrimidin-2-one beta-ribofuranoside and Acute Promyelocytic Leukemia
| Article | Year |
|---|---|
Epigenetic changes by zebularine leading to enhanced differentiation of human promyelocytic leukemia NB4 and KG1 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cytidine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Dose-Response Relationship, Drug; Drug Synergism; Epigenesis, Genetic; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2012 |
Antileukemic activity of combined epigenetic agents, DNMT inhibitors zebularine and RG108 with HDAC inhibitors, against promyelocytic leukemia HL-60 cells.
Topics: Acetylation; Cadherins; CD11b Antigen; Cell Differentiation; Cell Proliferation; CpG Islands; Cytidine; Enzyme Inhibitors; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histones; HL-60 Cells; Humans; Indoles; Leukemia, Promyelocytic, Acute; Methylation; Phthalimides; Promoter Regions, Genetic; Propionates; Tretinoin; Tryptophan | 2012 |